Compare GPMT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | ESLA |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 69.5M |
| IPO Year | N/A | N/A |
| Metric | GPMT | ESLA |
|---|---|---|
| Price | $1.51 | $1.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 119.7K | 44.8K |
| Earning Date | 05-05-2026 | 05-26-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $0.78 |
| 52 Week High | $3.12 | $3.15 |
| Indicator | GPMT | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 38.45 |
| Support Level | $1.24 | $0.96 |
| Resistance Level | $1.66 | $1.35 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 54.01 | 3.31 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.